Navigation Links
ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
Date:2/22/2008

rther studies on the combination use of Xibrom and Lucentis, and ISTA's goals of bringing a new product to market every 12 to 18 months and becoming the leading niche ophthalmic pharmaceutical company in the U.S., are forward-looking statements. Except as required by law, ISTA disclaims any intent or obligation to update any forward-looking statements. These forward- looking statements are based on ISTA's expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially. Important factors that could cause actual results to differ from current expectations include, among others: the inherent uncertainty associated with financial projections and estimates, timely and successful implementation of ISTA's strategic initiatives; delays and uncertainties related to ISTA's research and development programs (including without limitation the difficulty of predicting the timing or outcome of bepotastine product development efforts); the timing, scope, and outcome of FDA or other regulatory agency approval or actions; uncertainties and risks regarding market acceptance of and demand for ISTA's approved products; the impact of competitive technologies, products, and pricing; uncertainties and risks related to ISTA's ability to properly manage its growth; uncertainties and risks related to the continued availability of third-party sourced products and raw materials on commercially reasonable terms, or at all; uncertainties and risks related to successful compliance with FDA and/or other governmental regulations applicable to ISTA's facilities, products, and/or business; uncertainties and risks related to the scope, validity, and enforceability of patents related to ISTA's products and technologies and the impact of patents and other intellectual property rights held by third parties; and such other risks and uncertainties as detailed from time to time in ISTA's public filings with the U.S. Securities
'/>"/>
SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
2. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
3. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
6. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
7. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
8. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
9. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
10. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
11. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Calif. and BRUSSELS ... AMGN ) and UCB (Euronext Brussels: UCB) today ... evaluating effect of RomosozUmab Compared with Teriparatide in ... fracture pReviously treated with bisphosphonatE therapy). The study ... significant difference in favor of romosozumab in the ...
(Date:9/1/2015)... Sept. 1, 2015 Emerus Holdings, a ... emergent, inpatient and diagnostic care in partnership with ... a definitive agreement to receive a strategic investment ... a leading health care investment firm. ... patient-centric acute episodic and ambulatory clinical services to ...
(Date:9/1/2015)... IRVINE, Calif. , Sept. 1, 2015  Edwards ... in the science of heart valves and hemodynamic monitoring, ... Fargo Healthcare Conference at the Hyatt Regency Boston in ... 9, 2015. Michael A. Mussallem , ... keynote lunch speaker followed by a company discussion with ...
Breaking Medicine Technology:Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 4Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 5Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 6Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 7Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 8Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 9Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 2Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 3
... /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (NASDAQ: ... emerging leader in the development, assembly, marketing and sale ... that the Company,s growing business earned a BBB+ Credit Rating ... "Zhongguancun Association") and was approved as a member of ...
... SHANGHAI, Feb. 28, 2012 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: ... China-based pharmaceutical and biotechnology research and development outsourcing company, ... results for the fourth quarter and full year ended ... host a conference call to discuss the results at ...
Cached Medicine Technology:Dehaier Medical Awarded Strong Credit Rating From Beijing Zhongguancun Enterprises Credit Promotion Association 2Dehaier Medical Awarded Strong Credit Rating From Beijing Zhongguancun Enterprises Credit Promotion Association 3ShangPharma to Report Fourth Quarter and Full Year 2011 Financial Results on March 13, 2012 2
(Date:9/1/2015)... , ... September 01, 2015 , ... ... is now offering the MonaLisa Touch® , an innovative vaginal health laser ... Touch® is a new hormone-free treatment for atrophic vaginitis, a condition that causes ...
(Date:9/1/2015)... Florida (PRWEB) , ... September ... ... of Professional Background Screeners (NAPBS®) has announced that Edge Information Management ... conducted by the Background Screening Credentialing Council (BSCC). , “Achieving and ...
(Date:9/1/2015)... ... 01, 2015 , ... PetPace, the provider of an innovative ... activity, today announced its integration with leading veterinary Practice Management Software vendor Cornerstone. ... Practice Management Software packages in the US. Practice Management Software helps veterinarians manage ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... and government entities, announced today that it has hired Scott Sanderson, an experienced ... In this capacity, Sanderson will be responsible for establishing and managing new client ...
(Date:9/1/2015)... ... September 01, 2015 , ... Royal River Natural Foods, a ... followed men and women for 19 years and found that, among those who had ... multivitamins. , The report is part of the September 2015 issue of “Natural Insights ...
Breaking Medicine News(10 mins):Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3Health News:Edge Information Management Granted Continued NAPBS Accreditation 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 3Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2Health News:Former NFL Standout Scott Sanderson Joins eDiscovery Leader Discovia 2Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2
... ease the pain during labor. But such epidurals proved to ... Safety Agency (NPSA) in response has issued warnings to doctors ... 200 errors have been committed due a period of one ... at the base of the spine, but in some cases ...
Microsoft founder Bill Gates has said that his decision to devote more time to philanthropy was a...
... of partially hydrogenated oil laden with trans fats has targeted ... in the Public Interest filed the suit with the Superior ... either stop using partially hydrogenated oil or use signs to ... 50,000 Americans usually succumb to death annually because of using ...
... a united effort from the Western Australian Government and BHP ... health services //in the Pilbara, spread over a six year ... a post-natal depression support service in Newman. The Port Hedland ... ,While confirming that the construction of the hospital will ...
... tried to analyze the many reasons why some teen girls ... IVF treatments //. In his reading, they are just going ... ridiculed. ,Laurence Shaw, the deputy medical director of ... opinion that, it is the internal program charted by nature ...
... being exposed to too much light at night disrupts ... tumours //. Women particularly those who work night shifts ... particularly risk. ,For the first time now ... Institute of Environmental Health Sciences, have demonstrated that long ...
Cached Medicine News:Health News:Exposure To Artificial Light Could Be Cancerous 2
Reptilase-Time from Bothrops atrox...
Thrombin Activatable Fibrinolysis Inhibitor Assay Kit...
Pefakit TAFI Calibrators and Controls...
Plasma Control Level 2 - 1 ml...
Medicine Products: